Lever
Lifestyle
- Engage in regular aerobic exercise
- Maintain a healthy weight
- Avoid smoking
- Moderate alcohol consumption
Blutwerte · Marker
Apolipoprotein A1
ApoA1 · Apo A-I
Lipide & Herz-Kreislauf
- Einheit:
- g/L
- Abbreviation
- ApoA1
Apolipoprotein A1 quantifies the primary protein component of HDL involved in cholesterol transport.
Reference Ranges
Reference
1–1.8g/L
1
1.2
2
1.8
LowNormalHigh
Reference
Optimal
Unit · g/LReference ranges can vary slightly based on laboratory methods and population demographics.
Overview
Übersicht
Apolipoprotein A1 (ApoA1) is the primary protein component of high-density lipoprotein (HDL) in plasma. It plays a crucial role in the reverse transport of cholesterol from tissues to the liver for excretion, thus contributing to cholesterol homeostasis. ApoA1 is essential for the structural integrity and function of HDL particles, facilitating the activation of lecithin-cholesterol acyltransferase (LCAT), an enzyme critical for the conversion of free cholesterol into cholesteryl esters. Clinically, ApoA1 levels are inversely related to cardiovascular disease risk, with higher levels being protective against atherosclerosis. Researchers have found that ApoA1 is a significant marker in assessing lipid metabolism disturbances and immune dysfunction, particularly in conditions like acute-on-chronic liver failure and cryoglobulinemia. In the context of athletic performance and longevity, ApoA1 is relevant due to its role in lipid metabolism and cardiovascular health. Elevated ApoA1 levels are associated with enhanced lipid profiles and reduced cardiovascular risk, which are beneficial for athletes and those interested in biohacking for longevity. However, several factors can influence ApoA1 levels, including genetic variations, lifestyle factors, and acute inflammatory states. Fasting is generally not required for ApoA1 testing, but it is important to consider potential confounders such as recent intense exercise or acute illness that may temporarily alter levels.
Klinische Bedeutung
Elevated ApoA1 levels are associated with a reduced risk of cardiovascular diseases, while low levels may indicate an increased risk of atherosclerosis and cardiovascular events.
Dynamics
Trend Interpretation
Rising Values
Progressively rising ApoA1 levels suggest improved cardiovascular health. Re-test annually to monitor trends.
Falling Values
Falling ApoA1 levels may indicate increased cardiovascular risk or metabolic disturbances.
Re-test Interval
4 weeks if outside optimal range
Etiology
Causes — High & Low
Cause
Elevated Levels
- Regular physical activity
- High HDL cholesterol levels
- Genetic factors
- Estrogen therapy
- Moderate alcohol consumption
Cause
Low Levels
- Metabolic syndrome
- Chronic liver disease
- Inflammatory states
- Poor diet
- Smoking
Protocol
How to Optimize
Lever
Nutrition
- Increase intake of omega-3 fatty acids
- Consume more fruits and vegetables
- Include nuts and seeds in diet
- Choose whole grains over refined grains
Lever
Supplementation
- Omega-3 fish oil
- Niacin
- Plant sterols
Note:
Consult a healthcare provider before starting any supplementation, especially if you have underlying health conditions.
Testing Guidelines
✓Fasting Not Required
✓Not Time-Sensitive
Testing Frequency
Annually for adults at risk of cardiovascular disease, more frequently if monitoring lipid therapy.
Interfering Factors
- Recent intense exercise
- Acute illness
- Hormonal fluctuations
Related Peptides & Hormones
Hdl Cholesterol
hormone or peptideCorrelated with
Open Research Questions
Current research suggests that reference ranges and optimal targets for Apolipoprotein A1 (ApoA1) in various clinical contexts, such as HBV-related acute-on-chronic liver failure and cryoglobulinemia, remain inadequately defined. Researchers have not yet established the impact of confounding factors like age, sex, and comorbidities on ApoA1 levels. Additionally, clinical questions regarding the precise role of ApoA1 in immune dysfunction and its potential as a therapeutic target in amyloidosis require further investigation.
29 Research Publications
335
Total Citations
18
Human/RCT
1.0
Avg. Influence
2025
Latest
Sort
Filter
01Top
#01
Blood-based biomarkers for Parkinson's disease.
ReviewInfluence1.0
141
This review discussed the search for blood-based biomarkers for Parkinson's disease, identifying Apolipoprotein A1 as a potential candidate. Researchers noted the challenges in biomarker discovery but highlighted the advantages of blood samples for non-invasive testing.
02Top
#02
Apolipoprotein A1 and B.
ReviewInfluence1.0
49
Researchers reviewed evidence indicating that Apolipoprotein A1 (Apo A-I) and Apolipoprotein B are more effective than traditional cholesterol measures in assessing vascular disease risk and monitoring low-density lipoprotein-lowering therapy. They suggest these apolipoproteins provide better insights into cardiovascular health.
03Top
#03
Serum apolipoprotein A-I depletion is causative to silica nanoparticles-induced cardiovascular damage.
Animal
48
Researchers found that silica nanoparticles can deplete Apolipoprotein A1 (ApoA1) from the bloodstream, leading to cardiovascular damage. The study suggests that maintaining ApoA1 levels may be important for mitigating the toxic effects of nanoparticle exposure.
04
#04
HDLs and the pathogenesis of atherosclerosis.
Schwertani Adel, et al. · Current opinion in cardiology · 2018
Review
18
This review discussed the role of HDL cholesterol as a cardiovascular health biomarker, noting that HDL's protective functions can be compromised in disease states. Researchers found that modifications to HDL components, including Apo A-I, may contribute to atherosclerosis.
Key findings
- 01Researchers observed that HDL cholesterol levels are not effective therapeutic targets for preventing heart disease.
- 02They found that HDL performs various protective functions against atherosclerosis that are independent of cholesterol levels.
- 03The study identified a protein, desmocollin 1, that may hinder HDL's beneficial roles in heart health.
05
#05
HDL Structure.
Review
16
Researchers examined the structure of high-density lipoprotein (HDL) and its various components, highlighting that Apolipoprotein A1 (Apo A-I) is the predominant apolipoprotein involved in HDL's atherogenic activities. They found that HDL's structure and composition play crucial roles in various physiological functions, including immune response and lipid metabolism.
06
#06
HDL-cholesterol confers sensitivity of immunotherapy in nasopharyngeal carcinoma via remodeling tumor-associated macrophages towards the M1 phenotype.
Human
11
Researchers found that higher levels of Apolipoprotein A1 (ApoA1) and HDL cholesterol were associated with improved responses to immunotherapy in nasopharyngeal carcinoma patients. The study suggested that ApoA1 mimetics could enhance therapeutic outcomes by modulating macrophage polarization.
07
#07
ApoA1/HDL and sepsis-associated vascular endothelial injury: a narrative review.
Guo Kailin, et al. · Critical care (London, England) · 2025
Review
8
Researchers reviewed the role of Apolipoprotein A1 (ApoA1) in sepsis, finding that its depletion is linked to vascular endothelial injury. They propose that ApoA1 may serve as a therapeutic target due to its protective mechanisms in maintaining endothelial health.
Key findings
- 01Researchers observed a strong connection between decreased ApoA1/HDL levels and endothelial damage during infections.
- 02They identified three protective mechanisms of ApoA1: reducing inflammation, maintaining blood vessel integrity, and restoring blood flow.
- 03The review suggests that therapies based on ApoA1, such as mimetic peptides and recombinant HDL, could be promising for treating sepsis.
08
#08
Association between serum apolipoprotein B and atrial fibrillation: a case-control study.
Human
8
This study examined the association between Apolipoprotein B (ApoB) levels and atrial fibrillation (AF). Researchers found that lower ApoB levels were linked to a protective effect against AF in both men and women, indicating its potential as a biomarker.
09
#09
APOA1 mRNA and serum APOA1 protein as diagnostic and prognostic biomarkers in gastric cancer.
Human
8
Researchers explored the prognostic value of Apolipoprotein A1 (APOA1) in gastric cancer, finding that lower levels were linked to poor prognosis. The study suggests that APOA1 could serve as a diagnostic and prognostic biomarker in managing gastric cancer.
10
#10
Levels and clinical significance of the m6A methyltransferase METTL14 in patients with coronary heart disease.
Human
7
This study examined the relationship between METTL14 expression and coronary heart disease (CHD). Researchers found that higher METTL14 levels were associated with increased inflammatory markers and could independently predict CHD risk.
Publication Trend
Research publications about Apolipoprotein A1 over time
10totalTrack your bloodwork in PepStack
Log lab results, track trends and optimize your biomarkers over time.
Legal Disclaimer
This page is for informational and research purposes only. All information is based on published scientific literature and does not constitute medical advice, diagnosis, or treatment recommendations. Many substances listed may not be approved for human use and may be subject to drug regulation laws (e.g., AMG in Germany, FDA in the US). PepStack does not encourage the use of any substance on humans. Always consult a qualified healthcare professional before making any health-related decisions. Use of this information is entirely at your own risk. PepStack assumes no liability for the accuracy, completeness, or timeliness of the content provided. Full disclaimer